NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see how well the study drug, axitinib, helps control renal
(kidney) cancer that has come back (recurrent) or spread (metastatic). Patients must have
already been treated as a participant in a clinical trial with sunitinib, sorafenib,
pazopanib or placebo (sugar pill) after their initial surgery.
This study will examine the effect of adjuvant tyrosine kinase inhibition (TKI) therapy
(sorafenib, sunitinib or pazopanib) on subsequent exposure to TKI with axitinib in the
first-line recurrent or metastatic setting.